Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Research & Development: 2015-2025

Historic Research & Development for Niagen Bioscience (NAGE) over the last 10 years, with Sep 2025 value amounting to $1.8 million.

  • Niagen Bioscience's Research & Development rose 39.15% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 1.28%. This contributed to the annual value of $6.0 million for FY2024, which is 21.34% up from last year.
  • Per Niagen Bioscience's latest filing, its Research & Development stood at $1.8 million for Q3 2025, which was up 14.55% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Research & Development registered a high of $2.1 million during Q1 2024, and its lowest value of $787,000 during Q1 2021.
  • For the 3-year period, Niagen Bioscience's Research & Development averaged around $1.4 million, with its median value being $1.3 million (2024).
  • As far as peak fluctuations go, Niagen Bioscience's Research & Development soared by 75.61% in 2024, and later slumped by 39.95% in 2025.
  • Over the past 5 years, Niagen Bioscience's Research & Development (Quarterly) stood at $1.0 million in 2021, then grew by 22.39% to $1.3 million in 2022, then dropped by 9.38% to $1.2 million in 2023, then climbed by 13.46% to $1.3 million in 2024, then skyrocketed by 39.15% to $1.8 million in 2025.
  • Its Research & Development stands at $1.8 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.3 million for Q1 2025.